Search results
Author(s):
Christian Müller
Added:
3 years ago
B-type natriuretic peptide (BNP) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) have been shown to be extremely helpful in the diagnosis and management of patients with heart failure (HF). These neurohormones are secreted from both the left and the right cardiac ventricle in response to ventricular volume expansion and pressure overload. BNP and NT-proBNP can be seen as…
View more
Author(s):
James L Januzzi
Added:
3 years ago
The use of natriuretic peptide testing has dramatically risen recently, in recognition of the value of these blood tests for assisting in the evaluation of patients with suspected heart failure (HF). B-type natriuretic peptide (BNP) is formed as a consequence of production of a 108-amino-acid precursor peptide that is synthesised within the cardiomyocyte; this 'pro-BNP108' is subsequently cleaved…
View more
Author(s):
Christian Müller
Added:
3 years ago
B-type natriuretic peptide (BNP) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) have been shown to be extremely helpful in the diagnosis and management of patients with heart failure (HF). These neurohormones are secreted from both the left and the right cardiac ventricle in response to ventricular volume expansion and pressure overload. BNP and NT-proBNP can be seen as…
View more
Author(s):
Johannes Mair
Added:
3 years ago
In 1981, de Bold et al.1 provided the definitive demonstration of the endocrine function of the heart by the description of atrial natriuretic peptide (ANP). This was followed by the identification of brain natriuretic peptide, or B-type natriuretic peptide (BNP), in 1988.2,3 This natriuretic peptide (NP) was originally discovered in the porcine brain, but it is synthesised, stored and released…
View more
Author(s):
Serge Masson
,
Roberto Latini
Added:
3 years ago
Chronic heart failure (HF) is a major cause of death and disability. Predicting patients at risk of death or further cardiovascular events that require more intense monitoring and therapy is clinically challenging. Several factors are associated with increased mortality and morbidity in patients with HF, including age, a history of diabetes mellitus or renal dysfunction, advanced functional…
View more
Author(s):
Roland RJ van Kimmenade
,
James L Januzzi
Added:
3 years ago
Heart failure (HF) is currently achieving epidemic proportions, representing the single fastest-growing diagnosis among patients aged >65 years of age and the most common cause for hospitalisation in these patients.1 In addition to having a high incidence and prevalence, HF is associated with substandard clinical outcomes and with high rates of hospitalisation and death.1 Accordingly, great…
View more
Natriuretic Peptides - A Review
Author(s):
PO Collinson
Added:
3 years ago
Article
B-type Natriuretic Peptides in the Management of Acute Heart Failure and Acute Coronary Syndromes
Author(s):
Torbjørn Omland
Added:
3 years ago
Article
Author(s):
Venu Menon
Added:
3 years ago
Background
The management of patients with stable coronary artery disease (CAD) is characterised by the utilisation of proven medical therapy and on-going effective risk stratification. Periodic assessment of patient symptomatology and functionality; evaluation and control of traditional risk factors; presence and extent of ischaemia; extent of CAD and left ventricular (LV) function; and…
View more
Author(s):
Thomas Wolber
Added:
3 years ago
Coronary artery disease (CAD) is the leading cause of death in adults, accounting for more than 480,000 deaths in the US and 1.95 million deaths in Europe each year. There is considerable interest in early diagnosis of CAD, because obstructive coronary artery disease can exist with minimal or no symptoms and can progress rapidly. In patients with symptoms suggestive of CAD, a variety of tests and…
View more